Clarivate Plc (NYSE:CLVT), a provider of transformative intelligence, announced on Wednesday that it has enhanced its translational safety platform OFF-X with the integration of Pathway Maps, offering visual and data-driven tools to accelerate target safety assessments in drug development.

With safety concerns accounting for over 30% of drug development failures, the update addresses a critical need for early risk identification. Pathway Maps overlay curated multi-source safety data onto disease-specific signaling pathways and molecular processes, allowing R&D teams to pinpoint potential liabilities and make faster, more confident go/no-go decisions.

This enhancement streamlines fragmented safety data collection by combining biological context with risk intelligence in a single platform. The integration of OFF-X with Cortellis Drug Discovery Intelligence further strengthens Clarivate's offering, unifying efficacy and safety insights across the drug development lifecycle.

Clarivate continues to expand its footprint in Life Sciences & Healthcare by delivering enriched analytics and workflow solutions that support translational research from discovery through post-market surveillance.